EQS-News: PharmaSGP Holding SE holds 2025 Annual General Meeting 

PharmaSGP Holding SE holds 2025 Annual General Meeting 

• 91.12% of the registered share capital was represented
• Minimum dividend of €0.05 per dividend-bearing share resolved
• Management Board reports on successful operational development in 2024; forecast for current fiscal year 2025 confirmed

Gräfelfing, June 26, 2025 – German OTC pharmaceutical company PharmaSGP Holding SE held its 2025 Annual General Meeting yesterday as an in-person event at its headquarters in Gräfelfing. The share capital represented amounted to 91.12%.

At the Annual General Meeting, the Management Board reported on the successful 2024 financial year. Compared to the previous year, revenues grew by 17.5% to €118.8 million (previous year: €101.1 million). Adjusted earnings before interest, taxes, depreciation, and amortization (adjusted EBITDA) also increased by 9.2% from €34.1 million in 2023 to €37.2 million in fiscal year 2024. The adjusted EBITDA margin was 31.3% (previous year: 33.7%).

In accordance with the existing dividend policy, the Management Board and Supervisory Board had originally proposed to the Annual General Meeting the payment of a dividend of €0.51 per dividend-bearing share. In light of the delisting offer announced on June 10, 2025, FUTRUE GmbH, as the bidder and majority shareholder, submitted a counterproposal at the Annual General Meeting to approve the statutory minimum dividend of €0.05 per PharmaSGP share. This is intended to ensure that PharmaSGP shareholders can be granted the announced offer price of €28.00 per share without deduction of previously distributed dividends. The Annual General Meeting approved the counterproposal and resolved to distribute the statutory minimum dividend of €0.05 per PharmaSGP share.

The company also provided information on its current business development and confirmed its forecast for the ongoing 2025 financial year. The forecast takes into account, among other things, the continuing geopolitical and economic uncertainties. The Management Board expects revenues in a range between €122.0 million and €128.0 million. This represents average growth of around 5% compared with the previous year. Adjusted EBITDA is forecast to be between €37.0 million and €39.0 million. This corresponds to an adjusted EBITDA margin of 28.9% to 32.0%. In the first quarter of 2025, PharmaSGP achieved revenues growth of 10.8% to €33.5 million. Adjusted EBITDA increased by 4.0% to €9.2 million compared to the same period last year. The resulting adjusted EBITDA margin was 27.5% (previous year's quarter: 29.4%).

The detailed voting results for the Annual General Meeting 2025 are available for download on PharmaSGP's corporate website in the Investor Relations / Annual General Meeting section. 

CONTACT

cometis AG
Jakob Hafer
Phone: +49-611-20585522
Email: ir@pharmasgp.com
 

ABOUT PHARMASGP HOLDING SE

PharmaSGP is a leading consumer health company with a diversified portfolio of over-the-counter (OTC) pharmaceuticals and other healthcare products that are marketed with a focus on the pharmacy distribution channel. These products are mostly based on natural active pharmaceutical ingredients with documented efficacy and few known side effects.

The Company’s core brands cover chronic indications, including rheumatic pain, nerve pain and other age-related ailments. In Germany, PharmaSGP is the market leader for systemic chemical-free pain remedies with its brand families RubaXX^® for rheumatic pain and Restaxil^® for neuralgic pain. Furthermore, PharmaSGP also offers leading products against sexual weakness and vertigo symptoms. Since introducing the first product from the current product portfolio in 2012, PharmaSGP has successfully established its business model in other European countries, including Austria, Italy, Belgium, Spain and France. In September 2021, the product portfolio was expanded by the brands Baldriparan^®, Formigran^®, Spalt^® and Kamol^®, thus also strengthening or developing the indications pain and sleep disorder. The sales territory was expanded to include Switzerland and Eastern Europe. In 2024, PharmaSGP generated revenues of €118.8 million at an adjusted EBITDA margin of 31.3%.

In order to further expand its competitive position, PharmaSGP plans to increase the number of indications covered by PharmaSGP’s product offering, increase PharmaSGP’s European footprint, and accelerate its growth strategy especially by capitalizing on selected M&A opportunities.